Compare Global X Copper Miners ETF (COPX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Gilead Sciences, Inc. — how do they compare? Global X Copper Miners ETF trades at $85.6 (market cap $7.10B), while Gilead Sciences, Inc. trades at $150.68 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 25.7× Global X Copper Miners ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Gilead Sciences, Inc. for 111 Days on average.
| COPX | GILD | |
|---|---|---|
Market Cap | $7.10B | $182.40B |
Volume | 2,871,128 | 4,469,821 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $155.80 |
52-Week Low | $57.43 | $116.74 |
Typical Hold Time | 50 Days | 111 Days |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX trades at $84.83, up 1.5% today, but technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The ETF faces resistance at $85 with support at $79. Recent news highlights copper's strategic importance for AI infrastructure and electrification, though analysts express caution about near-term global surplus projections despite strong copper price fundamentals.
The copper miner ETF offers exposure to the AI-driven copper demand story but faces headwinds from Federal Reserve policy uncertainty and potential global supply surpluses. While long-term electrification trends support the investment thesis, near-term volatility and miner underperformance relative to copper prices present both opportunity and risk for investors.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
